Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy

2013 ◽  
Vol 62 (5) ◽  
pp. 723-730 ◽  
Author(s):  
Changzheng Du ◽  
Jun Zhao ◽  
Weicheng Xue ◽  
Fangyuan Dou ◽  
Jin Gu
Keyword(s):  
Rectal Cancer ◽  
Microsatellite Instability ◽  
Prognostic Value ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Neoadjuvant Radiotherapy

Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer

2018 ◽  
Vol 226 ◽  
pp. 15-23 ◽  
Author(s):  
Yvonne H. Sada ◽  
Hop S. Tran Cao ◽  
George J. Chang ◽  
Avo Artinyan ◽  
Benjamin L. Musher ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Treatment Response ◽  
Prognostic Value ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer

Prognostic Value of Pretreatment Serum CA199 in Patients with Locally Advanced Rectal Cancer Treated with CRT Followed by TME with Normal Pretreatment Carcinoembryonic Antigen Levels

2020 ◽  
pp. 1-6
Author(s):  
Daxin Huang ◽  
Qingliang Lin ◽  
Jianyuan Song ◽  
Benhua Xu
Keyword(s):  
Rectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Prognostic Value ◽  
Locally Advanced ◽  
Prognostic Significance ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Carbohydrate Antigen ◽  
Curative Surgery ◽  
Pretreatment Serum

<b><i>Background:</i></b> Elevated pretreatment carcinoembryonic antigen (CEA) levels are related to poor prognosis in patients with locally advanced rectal cancer (LARC) treated with neo-CRT followed by TME. In patients with normal pretreatment CEA levels, the prognostic significance of carbohydrate antigen 199 (CA199) is controversial. <b><i>Objectives:</i></b> The aim of this study was to explore the prognostic value of pretreatment serum CA199 in patients with LARC who had normal pretreatment CEA levels treated with neo-CRT followed by curative surgery. <b><i>Methods:</i></b> A retrospective study of 456 patients with LARC treated with neo-CRT followed by TME between January 2006 and May 2017 was performed. We employed the maximal χ<sup>2</sup> method to determine the CA199 threshold of 9.1 U/mL based on the difference in survival and divided patients into 2 groups. Group 1: patients with pretreatment s-CEA &#x3c; 5 ng/mL and CA199 ≥ 9.1 U/mL. Group 2: patients with pretreatment s-CEA &#x3c; 5 ng/mL and CA199 &#x3c; 9.1 U/mL. Overall survival (OS) across CA199 was assessed using Cox proportional hazard regression models (PS:CEA ≥ 5 ng/mL was seen as elevated). <b><i>Results:</i></b> Multivariate analyses demonstrated that the following factors were significantly related to OS in patients with LARC with normal pretreatment CEA levels: ypT (odds ratio [OR] 1.863, <i>p</i> = 0.030), ypN (OR 1.622, <i>p</i> = 0.026), and pretreatment CA199 levels (OR 1.886, <i>p</i> = 0.048). <b><i>Conclusion:</i></b> Pretreatment CA199 is an independent factor for OS in patients with LARC with normal pretreatment CEA levels, which may reach the clinic to guide individualized decision-making.

scholarly journals Clinical and pathological outcomes of induction chemotherapy before neoadjuvant radiotherapy in locally‐advanced rectal cancer

2019 ◽  
Vol 120 (2) ◽  
pp. 308-315
Author(s):  
Karin M. Hardiman ◽  
Alexis G. Antunez ◽  
Arielle Kanters ◽  
Ari D. Schuman ◽  
Scott E. Regenbogen
Keyword(s):  
Rectal Cancer ◽  
Induction Chemotherapy ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Neoadjuvant Radiotherapy
Sign in / Sign up

Export Citation Format

Share Document